Issue: November 2017
October 10, 2017
2 min read

Bictegravir with F/TAF noninferior to boosted PI regimens in HIV

Issue: November 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN DIEGO — Switching to an HIV regimen containing bictegravir was virologically noninferior to remaining on stable boosted protease inhibitor-based regimens in a recent phase 3 trial.

The bictegravir-containing regimen was also a safe alternative to the others, researchers said.

Previous trials have shown that bictegravir with emtricitabine/tenofovir alafenamide (F/TAF) is effective, study researcher Eric S. Daar, MD, chief of the division of HIV medicine at the Harbor-UCLA Medical Center and professor of medicine at the David Geffen School of Medicine at UCLA, said during a presentation.

Bictegravir is a novel, potent integrase strand transfer inhibitor with a high in vitro barrier to resistance and low potential for drug-drug interactions and is coformulated in a single tablet regimen with emtricitabine/tenofovir alafenamide for once-daily dosing,” Daar said.

In their study, Daar and colleagues included a total of 577 virologically suppressed adults with HIV on a boosted protease inhibitor (bPI)-based regimen with two nucleoside reverse-transcriptase inhibitors. Of those, 287 were randomly assigned to continue their existing bPI-based regimens consisting of boosted atazanavir or darunavir plus abacavir/lamivudine (ABC/3TC) or emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).

The other 290 patients switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) once daily.

The median patient age was 48 years, and approximately 85% were receiving FTC/TDF at screening.

At 48 weeks, 1.7% of patients in each study arm had HIV RNA of 50 c/mL or more.  In addition, 92.1% of patients receiving B/F/TAF had HIV RNA less than 50 c/mL, compared with 88.9% of those receiving a bPI-based regimen.

No patient receiving B/F/TAF developed resistance to the study drugs, discontinued treatment due to renal problems or experienced tubulopathy, the researchers said.

“B/F/TAF was well-tolerated and adverse events were comparable between study arms, with the exception of mild headaches that occurred more frequently in the B/F/TAF arm,”
Daar said. “But these tended to be relatively mild, transient and low grade.”

Darunavir is sold under the brand name Prezista (Janssen), FTC/TDF is sold under the brand name Truvada (Gilead Sciences), F/TAF is sold under the brand name Descovy (Gilead Sciences) and atazanavir is sold under the brand name Reyataz (Bristol-Myers Squibb). – by Joe Green


Daar E, et al. Abstract LB-4. Presented at: IDWeek; Oct. 4-8, 2017, San Diego.

Disclosures: Daar reports working as a consultant for and receiving consulting fees from Bristol-Myers Squibb; working as a paid consultant, grant investigator and scientific advisor for, and receiving research support and consulting fees from, Gilead Sciences, Janssen, Merck and ViiV Healthcare; and working as a consultant and scientific advisor for, and receiving consulting fees from, Teva Pharmaceuticals. Please see the study for all other authors’ relevant financial disclosures.